NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025


The two NUS Medicine researchers and co-founders of AGeM Bio, Dr Sarah Ho (left) and Dr Woo Jun Yung (right), with Clinical Associate Professor Yeo Tseng Tsai from the National University Hospital’s Division of Neurosurgery - The Straits Times

SINGAPORE: In the future, patients who suffer a relapse of the deadliest form of brain cancer may get a second shot at life with the help of a novel gene therapy developed by researchers from the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine).

The scientists behind the stem cell-based gene therapy are aiming to start a clinical trial for glioblastoma patients at the National University Hospital (NUH) by late 2025.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Aseanplus News

Philippines’ main coal mine in limbo puts nation’s energy supply at risk
Man who sexually assaulted oldest stepdaughter gets nearly 12 years’ jail, caning
China confirms first Xi-Trump-Putin summit on Nov 19
Thai Airways addresses emergency landing of Munich–Bangkok flight
Garment-makers threaten to quit wage talks
Youngsters use AI to create fake funeral posts
Asean leaders seek to advance peace plan with junta
Canberra, Manila seal defence pact
Top scorer admits cheating
Trade tensions shadow summit

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read